jolt-ca

Joint Lung Cancer Trialist's Coalition
Newsletter for Clinical Trial Partners / JULY 2018

UTSouthwestern
Harold C. Simmons
Comprehensive Cancer Center
Radiation Oncology

Congratulations! We are pleased to announce that the Stablemates Trial has reached a significant milestone by enrolling 102 patients to date. This has been an outstanding effort by all sites involved and we greatly appreciate everyone's dedication to this important international trial.



TIPS:

• Please remember to upload eligibility checklist and consent within two business days of completion. Treatment and follow-up information should be entered within 30 days of the visit/end of treatment.

• Based on feedback from sites, as well as points from our recent audit, we will be conducting training sessions to go through aspects of the trial that are confusing or may need clarification, such as REDCap and the study calendar. Once we have more information, a formal notice of the training will be sent out to all potential participants.

• If a patient has an SAE per protocol section 11.4, please fill out the SAE form on the Jolt webpage and submit to Sarah Hardee. All deaths need to be reported regardless of relatedness. If there are questions about whether or not something needs to be reported, please contact Sarah.

• Make sure the eligibility checklist is signed off by the appropriate parties to meet the criteria.

• Please do not contact IROC for credentialing documentation. *Visit the Stablemates website at* ***www.joltca.org.***

A Randomized Phase III Study of Sublobar Resection (SR) versus Stereotactic Ablative Radiotherapy (SAbR) in High-Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)

STABLEMATES TRIAL

jolt-ca

Joint Lung Cancer Trialist's Coalition

Newsletter for Clinical Trial Partners / JULY 2018

Congratulations! We are pleased to announce that the Stablemates Trial has reached a significant milestone by enrolling 102 patients to date. This has been an outstanding effort by all sites involved and we greatly appreciate everyone's dedication to this important international trial.

SUBSITE UPDATE

Active:

- Anne Arundel Medical Center
- Boston University
- Cardiothoracic and Vascular Surgeons - Austin
- Case Western
- CHUM-Notre Dame Hospital
- Cleveland Clinic
- Henry Ford Health System
- INOVA
- Intermountain Medical Center
- Lifespan Oncology Clinical Research
- Medical College of Wisconsin
- Memorial Health University
- Meridian Health
- New York University
- Ochsner Medical Center
- Ohio State University
- Ottawa
- Penn State (Mount Nittany Medical Center)
- Penrose Cancer Center
- Providence Health and Services
- St. Vincent's – Australia
- SUNY
- Swedish Cancer Institute
- Thomas Jefferson University
- University of California San Diego
- UHN - Toronto General Hospital
- University of Cincinnati
- University of Colorado/Memorial
- University of Iowa
- University of Kansas
- University of Louisville Physicians
- University of North Carolina Chapel Hill
- UT Southwestern Medical Center
- University of Virginia
- West Clinic/University of Tennessee
- William Beaumont Hospital

Completed contracts:

- Sunnybrook

Completed IRB approval:

- CERV
- UPMC

If there are any questions regarding how to enter data screen patients or any aspect of the trial, please email or call Sarah.

Study Co-Chair & Surgery QA Study — Hiran Fernando, MD | hiran.fernando@inova.org | 703.776.3563
Co-Chair & Radiation QA — Robert Timmerman, MD | robert.timmerman@utsw.edu | 214.645.7651
Statistician — Chul Ahn, PhD | chul.ahn@utsw.edu | 214.648.9418
Clinical Research Coordinator — Sarah Hardee Neufeld, MS | sarah.hardee@utsw.edu | 214.648.1836
Research Manager — Sarmistha Sen, MS, MHA | sarmistha.sen@utsw.edu | 214.645.1477